Site icon pharmaceutical daily

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hodgkin
Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1 2019”

drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1
2019
provides comprehensive information on the therapeutics
under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
(Oncology) pipeline guide also reviews key players involved in
therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical and Unknown stages are 2, 2, 43, 29, 1, 13 and 1
respectively. Similarly, the Universities portfolio in Phase II, Phase
I, Preclinical and Discovery stages comprises 6, 3, 2 and 1 molecules,
respectively.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide
helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.

Scope

Reasons to Buy

Key Topics Covered

  1. Introduction
  2. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview
  3. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development
  4. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment
  5. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in
    Therapeutics Development
  6. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles
  7. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects
  8. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products
  9. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development
    Milestones
  10. Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5e6axt

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Lymphoma
Drugs

Exit mobile version